Role of antidepressant drugs in migraine treatment

Yıl 2019, Cilt: 44 Sayı: Ek 1, 555 - 566, 29.12.2019

Fatih Berktaş , Emine Ekemen , Olcay Kıroğlu , Fazilet Aksu

https://doi.org/10.17826/cumj.570837

Cited By: 1

Öz

Migraine is a type of headache with a throbbing character that begins at childhood, adolescence or early adulthood, often accompanied by symptoms such as nausea, light and sound sensitivity. Depression is the most common psychiatric disorder among migraine patients. Migraine and depression affect many people and have a similar prevalence of about 10 and 15%. If migraine treatment is incomplete, depression may occur as a result of the helplessness. Treatment in migraine is carried out in two stages; acute attack and prophylactic treatment. While analgesics, non-steroidal antiinflammatory drugs, ergot alkaloids and triptans are used in acute attack, drugs such as beta blockers, antiepileptics, antidepressants are used in prophylactic treatment. The success of these drugs in reducing the number and severity of attacks in patients can not be achieved with full success. Therefore, the effects of different antidepressant drug groups are investigated. Selective serotonin reuptake inhibitors (SSRIs), selective serotonin-noradrenaline reuptake inhibitors(SNRIs) and especially tricyclic antidepressants (TCA) are preferred especially with depression, stress, anxiety and sleep disturbance in the prophylactic pharmacological treatment of patients with frequent migraine attacks. In this study we aimed to investigate the effects of antidepressants used in migraine treatment on the severity and duration of migraine.

Anahtar Kelimeler

Migraine, Antidepressants, Depression, Treatment

Migren tedavisinde antidepresan ilaçların rolü

Öz

Migren, çocukluk, ergenlik veya erken erişkin dönemde başlayan, sıklıkla bulantı, ışık ve ses duyarlılığı gibi semptomların eşlik ettiği, periyodik aralıklarla gelen zonklayıcı karakterde bir baş ağrısı türüdür. Migrenli hastalarda en çok görülen psikiyatrik bozukluklarda ilk sırada depresyon yer almaktadır. Migren ve depresyon birçok kişiyi etkiler ve yaklaşık %10-15 dolayında benzer prevalansa sahiptir. Migren tedavisi eğer eksik yapılırsa durumun kontrol edilemez olmasının getirdiği çaresizliğin sonucunda hastalarda depresyon ortaya çıkabilmektedir. Migrenin akut ataklarının profilaksi ve tedavisi iki aşamada gerçekleştirilmektedir. Akut atakta; analjezikler ve non-steroid antiinflamatuar ilaçlar, ergot alkoloidleri ve triptanlar kullanılırken, profilaktik tedavide; beta blokörler, antiepileptikler, antidepresanlar, kalsiyum kanal blokörleri gibi ilaçlar kullanılmaktadır. Bu ilaçlarla hastalarda atakların sayısının ve şiddetinin azaltılmasında tam bir başarı elde edilememektedir. Bu sebeple son zamanlarda antidepresan ilaç gruplarının tedavideki yeri araştırılmaktadır. Özellikle depresyon, stres, anksiyete ve uyku bozukluğu ile birlikte sık migren atağı geçirenlerin, profilaktik farmakolojik tedavisinde başta trisiklik antidepresanlar (TSA) olmak üzere, selektif serotonin geri alım inhibitörleri (SSRI) ve selektif serotonin-noradrenalin geri alım inhibitörleri (SNRI) tercih edilmektedir. Bu çalışmamızda migren tedavisinde kullanılan antidepresanların migrenin şiddeti ve süresindeki etkilerini incelemek amaçlanmıştır.

Anahtar Kelimeler

: Migren, Antidepresanlar, Depresyon, Tedavi

Kaynakça

• 1. Bıçakçı Ş, Başağrılarında Yeni Sınıflama, Türkiye Klinikleri Nöroloji Dergisi. 2003; 1(2):85-93.
• 2. Bolay H, Dalkara T. Birincil Baş ağrılarının Fizyopatolojisi. Türkiye Klin Dahili Tıp Bilim Nöroloji Derg Başağrısı Özel Sayısı. 2003;1(2):98-102.
• 3. Lipton RB, Bigal ME. Ten lessons on the epidemiology of migraine. Headache: The Journal of Head and Face. Pain. 2007;47:2-9.
• 4. Holm JE, Lokken C, Myers TC. Migraine and stress: a Daily examination of temporal relationships in women migraineurs. Headache: The Journal of Head and Face. Pain. 1997;37(9), 553-8.
• 5. Karayağız Ş. Bipolar ve Unipolar Depresyonda Aleksitimi Düzeylerinin Karşılaştırılması ve Yaşam Kalitesi İle İlişkisi, Kayseri: Erciyes Üniversitesi Psikiyatri Anabilimdalı 2013.
• 6. Alonso C, Loevinger BL, Muller D, Coe CL. Menstrual cycle influences on pain and emotion in women with fibromyalgia.J Psychosom Res. 2004;57(5):451-8.
• 7. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004; 111:77-83.
• 8. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46(4):642-8.
• 9. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep. 2003;7(1):51-4.
• 10. Lipton RB. ve Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache, 2005;45: 3-13.
• 11. Silberstein SD, Lipton RB, Goadsby PJ. Klinik Uygulamada Basağrısı. (Martin Dunitz Ltd. Londra,2002) Türkçe ed.:Ertas M, Akman-Demir G. Yelkovan Yayınları, 2004; 1-113.
• 12. Ward TN. Migraine diagnosis and pathophysiology. Continuum, 2012;18:753-63.
• 13. Headache Classification Committee of the İnternational Headache Society (IHS). The international classification of headache disorders (beta version). Cephalalgia. 2013;33(9):629-808.
• 14. Lipton RB, Goadsby P, Silberstein SD. Classification and epidemiology of headache. Headache in primary care 1999;1(6):1-10.
• 15. Huang GB, Yao LT, Hou JX, Zhang ZJ, Xin YT, Wu XY. et al. Epidemiology of migraine in the She ethnic minority group in Fujian province, China. Neurological Research, 2013; 35(7):684-92.
• 16. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A. et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62(5): 788-90.
• 17. İncekara AF. Migren hastalarında nörolojik ve psikiyatrik komorbidite, Nöroloji Anabilim Dalı, Uzmanlık Tezi, Süleyman Demirel Üniversitesi Tıp Fakültesi; 2010
• 18. Üneri Ö, Şenbil N, Turgut S. Migrenli Ergenlerde Yaşam Kalitesi. Anadolu Psikiyatri Dergisi, 2009; 10:137-41.
• 19. Edmeads J. The treatment of headache: a historical perspective. In: Gallagher RM, ed. Therapy forheadache. New York: Marcel Decker Inc. 1990: 1-8.
• 20. Adams RD, Victor M. Principles of neurology, 7th edition, Mc Graw Hill international editions. 2001, Chapter 10.
• 21. Rasmussen BK. Epidemiology of headache. Cephalalgia. 2001; 21(7):774-7.
• 22. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies. Headache. 2013;53(3):427-36.
• 23. Olesen J, Goadsbay PJ, Ramadan MN, Hansen PT, Welch KM. Epidemiology of migraine. In: The Headaches. 3 th edi.Lıppıncott Williams&Wılkıns; 2006:235-41.
• 24. Siva A. Basağrısı epidemiyolojisi. Türkiye Klinikleri Nöroloji. 2003;1(2):94-7.
• 25. Ertas M, Baykan B, Kocasoy OE et al. One-year prevalence and the impact of migraine and tension-type headache in Turkey: A nationwide home-based study in adults. J Headache Pain. 2012;13(2):147-57.
• 26. Silberstein SD, Lipton RB, Dalessio DJ. Headache: Epidemiology and Impact. In: Wolff’s Headache and Other Head Pain. 8 th edi. New York:Oxford University Press;2008:45-62.
• 27. Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, et al. Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy versus polytherapy. Headache.2007;47(4):585–99.
• 28. Jensen R. Pathophsiological mechanisms of tension type headache: a review of epidemiological and experimental study. Cephalalgia. 1999; 19 (6): 602-21.
• 29. Ambrosini A, Schoenen J. The electrophysiology of migraine. Curr Opin Neurol. 2003;16(3):327–31.
• 30. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619–29.
• 31. Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM, et al. Genome-wide associationanalysis identifies susceptibility loci for migraine without aura. Nat Genet. 2012;44(7):777–82.
• 32. Durham PL, Vause C V. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs.2010;24(7):539–48.
• 33. Bolay H, Dalkara T. Birincil Baş ağrılarının Fizyopatolojisi. Türkiye Klin Dahili Tıp Bilim Nöroloji Derg Başağrısı Özel Sayısı. 2003;1(2):98-102.
• 34. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004;24(2):2-7.
• 35. Bolay H, Reuter U, Dunn A, Huang Z, Boas D, Moskowitz A. İntrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine, 2002; 8 (2): 136-42.
• 36. Bigal ME, Walter S, Rapoport AM. The vasodilatory activity of CGRP: a response. Headache. 2014;54(4):748–9.
• 37. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol.2004;500(1-3):315–30.
• 38. Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician. 2016;19(1): 97-112.
• 39. Afridi SK, Matharu MS, Lee L et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128(4):932-9.
• 40. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56(3):371-81.
• 41. Cutrer FM, Sorensen AG, Weisskoff RMet al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol. 1998;43(1):25-31.
• 42. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B. et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences of the United States of America, 2001;98(8), 4687-92.
• 43. Goetz CG. Textbook of Clinical Neurology. Chiacago:Saunders;2007:1261-306.
• 44. Özdemir GY, Qiu J, Matsuoka N, Bolay H, Bermphol D, Rosenberg GA et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004;113(10):1447-55.
• 45. Di Lorenzo C, Pierelli F, Coppola G, Grieco GS, Rengo C, Ciccolella M. et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology. 2009; 72:1588-94.
• 46. Ferrari MD. Biochemistry of migraine. Path Biol. 1992;40:287-92.
• 47. Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache.2006;2:55-60.
• 48. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27(11):1293-300.
• 49. Guyton A, Hall J(Çeviri: Çavuşoğlu H). Tıbbi Fizyoloji. Kan Akımının Dokular Tarafından Lokal Kontrolü ve Hormonal Düzenlenme. 9 th ed. İstanbul:Nobel Tıp Kitabevi;1996:199-208.
• 50. Ferrari MD, Odink J, Tapparelli C, Van Kempen GMJ, Pennings EJM, Bruyn GW. Serotonin metabolism in migraine. Neurology. 1989;39(9):1239-39.
• 51. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci. 1990;600:587-98.
• 52. Ertas M, Baykan B, Orhan EK, Zarifoglu M, Karli N, Saip S, et al. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nation wide home-based study in adults. J Headache Pain. 2012;13(2):147–57. 53. Mathew NT. Migren, Bölüm 2. Basağrısı El Kitabı. (Lippincott Williams&Wilkins, Philedelphia USA, 2.baskı, 2005) Türkçe Ed.:Ertas M, Ertas NK. Sigma yay. 2005:28-59.
• 54. Ertas M. Migren. Türkiye Klinikleri Nöroloji Dergisi. 2003; 1(2):116-23.
• 55. Zarifoğlu M. Bas ağrıları. İçinde: Klinik Nöroloji, Oğul E.(ed.). 2002; Nobel & Günes, İstanbul, 105-30. 56. Saper J, Biandi D, MacGregor A. Klinisyenin El Kitabı Bas Ağrısı, 3.Baskı, İngiltere: Science Press Limited, 2001.
• 57. Wang SJ, Chen PK, Fuh JL. Comorbidities of migraine. Front Neurol. 2010;1:16.
• 58. Kurth T, Slomke MA, Kase CS, Cook NR, Lee LM, Gaziona JM et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology. 2005;64(6):1020-26.
• 59. İncekara AF, Kutluhan S, Yürekli VA, Demirci K, Akdağ C, Zengin E. Neurologic and Psychiatric Comorbidity in Migraine Patients. Turkiye Klin J Med Sci. 2013;33(1):59-66.
• 60. Teggi R, Caldirola D, Colombo B, Perna G, Comi G. Dizziness, migrainous vertigo and psychiatric disorders. The Journal of Laryngology & Otology 2010; 124, 285-90.
• 61. Pompili M, Serafini G, Di Cosimo D, Dominici G. Psychiatric comorbidity and suicide risk in patients with chronic migraine. Nuropsychiatr Dis Treat. 2010; 6:81-91.
• 62. Köknel Ö, Ruhsal Çöküntü: Depresyon, İstanbul: Altın Kitaplar Yayınevi, 6.Baskı, 2005, s.58.
• 63. Öztürk MO, Ulusahin A. Ruh Sağlığı ve Bozuklukları I, 11.Baskı. Ankara, Tuna Matbaacılık 2011;342-7.
• 64. Kececi H, Dener S, Analan E. Co-morbidity of migraine and major depression in the Turkish population. Cephalalgia. 2003; 23(4):271-5.
• 65. Sheftell FD, Atlas SJ. Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache. 2002;42(9):934–44.
• 66. Lanteri-Minet M, Radat F, Chautard MH, Lucas C. Anxiety and depression associated with migraine: influence on migraine subjects’ disability, quality of life and acute migraine management. Pain. 2005;118(3):319-26.
• 67. Karaca S, Demir F, Herken H, Demir O, Aşkın R. Kronik Ağrılı Ve Migrenli Hastalarda Depresyon Düzeyleri Ve Ağrı İle Başa Çıkma Becerileri 1, Düşünen Adam, 1999; 12:31-3.
• 68. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003; 60:1308- 12.
• 69. Serkan S. Farklı Öz-Anlayış Düzeylerine Sahip Üniversite Öğrencilerinde Depresyon, Anksiyete Ve Stresin Değerlendirilmesi, Selçuk Üniversitesi, Konya, 2008.
• 70. Kocabaş Z, Çelebi A. Migren Ve Gerilim Baş Ağrısında Anksiyete, Depresyon Ve Nörotik Eğilim Düzeyleri, Düşünen Adam, 1997; 10 (3):17-21.
• 71. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006; 46(9):1327
• 72. Zwart JA, Dyb G, Hagen K, Odegard KJ, Dahl AA, Bovim G, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trondelag Health Study. Eur J Neurol. 2003;10(2):147-52.
• 73. Siva A. Migren. İstanbul Üniversitesi Cerrahpaşa Tıp Fak Sürekli Tıp Eğitimi Etkinlikleri Sempozyumu. 2002;30:39-50.
• 74. Silberstein SD, Sapel JD, Freitag GF. Migraine Diagnosis and Treatment. In: Wollf’s Headache and other headpain.7th ed. Oxford University Pres;2001:201-37.
• 75. Linde M. Migraine: A review and future directions for treatment. Acta Neurol Scand. 2006;114(2):71-83.
• 76. Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14(5):330-8.
• 77. Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey KE et al. Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache. 2006;46(6):914-24.
• 78. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs. 2001;2(9):1261-8.
• 79. Yücesan C. Migren ve Tedavisi. Turkiye Klin J Neurol Spec Top. 2008;1(1):10-21.
• 80. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci. 1992;19(3):340-5.
• 81. Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713-5.
• 82. Horasanlı E, Usta B, Yesilay A. Medikal Akupunktur. Yeni Tıp Dergisi 2008;25:70-5.
• 83. Örsel S. Depresyonda Tedavi: Genel İlkeler ve Kullanılan Antidepresan İlaçlar. Klinik Psikiyatri 2004;4:17-24
• 84. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet. 1964;1:1236–9.
• 85. Mathew NT, Tfelt-Hansen P. General pharmocologic approach to migraine management. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen, Welch KMA. The Headaches 3rd ed. Philadelphia: Lippincott Williams & Wilkins. 2006: 433-40.
• 86. Ertaş M. Migren tedavisi. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Baş, Boyun, Bel Ağrıları Sempozyum Dizisi 2002; 30:51-4.
• 87. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32:101-4.
• 88. d’Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39:716-9.
• 89. Rampello L1, Alvano A, Chiechio S, Malaguarnera M, Raffaele R, Vecchio I, Nicoletti F. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology. 2004;50(4):322-8.
• 90. MacGregor EA, Frith AA, Hackshaw A. Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study. J Clin Psychopharmacol. 2011;31(3): 392-3.
• 91. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Annals of Internal Medicine. 2002;137(10):840–9.
• 92. Loder E, Burch R, Rizzoli P. The 2012 AHS/AANguidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930–45.93. Landy S, McGinnis J, Curlin D, Laizure SC. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache. 1999;39(1):28-32.
• 94. Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. on behalf of the Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society Guideline for Migraine Prophylaxis. Canadian Journal of Neurological Sciences. 2012; 39:1–2.
• 95. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. European Federation of Neurological Societies (EFNS) guideline on the drug treatment of migraine - revised report of an EFNS task force. European Journal of Neurology 2009; 16(9):968–81.
• 96. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004;107:44-8. 97. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005; 45:144-52.
• 98. Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;254-8.
• 99. Young WB1, Bradley KC, Anjum MW, Gebeline-Myers C. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. Headache. 2013;53(9):1430-7.
• 100. Munro G1, Jansen-Olesen I. Animal models of pain and migraine in drug discovery. Drug DiscovToday. 2017;22(7):1103-111.
• 101. Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. Duloxetine in the treatment of chronic migraine.Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):49-54. 102. Lévy E1, Margolese HC. Meneses A. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol. 2003;18(5):301-3.
• 103. Amelin AV, Skoromets AA, Korenko LA, Tumelevich BCh, Gonchar MA. A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period. Zh Nevrol Psikhiatr Im S S Korsakova. 2000;100(8):20-23.
• 104. Galletti F, Cupini LM, Corbelli I et al (2009) Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009;89(2):176–92
• 105. Saper JR, Silberstein SD, Lake AE III, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994;34:497-502.
• 106. B&rk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994;34:476-8.
• 107. Walker Z, Walker RWH, Robertson MM, Stansfeld S. Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine. Headache 1998;38(7):523–8.
• 108. Taylor AP, Adelman JU, Freeman MC. Efficacy of Duloxetine as a Migraine Preventive Medication: Possible Predictors of Response in a Retrospective Chart Review. Headache. 2007 ;47(8):1200-3.
• 109. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for migraine management: agomelatine. Clin Neuropharmacol. 2013;36(2):65-7.
• 110. Tabeeva GR, Sergeev AV, Gromova SA. Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan). Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(9):32-6.
• 111. Kathpal GS. Role of SSRIs in the management of migraine. Headache Q, Curr Treat Res. 1998;9:265-6.
• 112. Nascimento ED. Profilaxia da migranea. Estudo aberto a venlafaxina em 42 pacientes. Arq Neuropsiquiatr.1998;56:744-6.
• 113. Landy S1, McGinnis J, Curlin D, Laizure SC. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache. 1999;39(1):28-32.
• 114. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992;32:101-4.
• 115. Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: A randomized controlled trial. Neurology 2010; 75: 1527–32.
• 116. Plasencia-García BO, Romero-Guillena SL, Quirós López A, Ruiz-Doblado S. Agomelatine and migraine management: a successfully treated case series. Ther Adv Psychopharmacol. 2015;5(4):243-5